Alkem delivered a stable Q3 with total revenue of ₹3,737 crore (+10.7% YoY) and EBITDA margin of 22.2%.
✓ Verified against BSE filing
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
The government's MIP on penicillin derivatives could impact gross margins by 50-100 bps, though management expects to mitigate via pricing actions in trade generic business.
medium · analyst_questionOcclutech operates in a different segment (medtech) with complex regulatory and manufacturing requirements; integration and scaling may face challenges.
medium · analyst_questionUS entry for denosumab is subject to ongoing litigation with Amgen, which could delay launch beyond FY26.
high · management_commentaryTrade generic business has been flat to low single-digit growth due to competitive pressures and conscious margin protection, potentially dragging overall domestic growth.
low · data_observation